Article: Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development.

BETHESDA, Md., March 25 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today named five leading oncology and immunology researchers to its newly formed panel of BiTE(R) antibody advisors. Richard A. Flavell (Yale University, New Haven, Connecticut), Michael J. Keating (MD Anderson Cancer Center, Houston, Texas), Ronald Levy (Stanford University, Stanford, California), Jeffrey V. Ravetch (Rockefeller University, New York, New York), and Anthony W. Tolcher (South Texas Accelerated Research Therapeutics, San Antonio, Texas) will support the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!